Results 51 to 60 of about 5,281 (177)

Long‐term remission in gout: Challenges and future opportunities

Rheumatology &Autoimmunity, EarlyView.
Prolonged hyperuricemia is a major risk factor for gout, which is now regarded as a curable disease. Awareness of the various factors that can trigger gout flares is essential for their prevention. An important determinant of treatment decisions and long‐term follow‐up is the quality of the clinician–patient relationship. The “treat‐to‐target” approach
Patapong Towiwat, Zhanguo Li
wiley   +1 more source

Management of gout: Primary care approach

South African Family Practice, 2009
Great strides have been made in understanding gout as a disease over the centuries. Despite these advances, reports suggest that the management of gout is relatively sub-optimal at the primary care level.
Olufemi Omole, Gboyega A. Ogunbanjo
doaj   +1 more source

Farnesoid X receptor prevents hyperuricemia via activating ATP‐binding cassette subfamily G member 2

Rheumatology &Autoimmunity, EarlyView.
Farnesoid X receptor (FXR) activation reduces serum uric acid levels by upregulating the intestinal urate transporter ATP‐binding cassette subfamily G member 2 (ABCG2). These findings uncover a novel metabolic pathway for urate excretion and suggest that FXR agonists (e.g., obeticholic acid), represent a promising therapeutic strategy for the treatment
Rui Li, Guo Tang, Ye Yu, Guang‐Liang Chen, Liangjing Lu, Juan Wang   +5 more
wiley   +1 more source

Exploring a Subpopulation of MASLD Associated With New Onset of CKD Using Supervised Clustering Techniques

Hepatology Research, EarlyView.
The supervised clustering of metabolic dysfunction‐associated steatotic liver disease (MASLD) using a SHapley Additive exPlanations (SHAP)‐converted matrix reveals distinct subpopulations that improved risk stratification for new onset of chronic kidney disease (CKD).
Itaru Hosaka, Marenao Tanaka, Tatsuya Sato, Yukinori Akiyama, Keitaro Nishizawa, Rie Matsumori, Hiroki Aida, Wataru Kawaharata, Kei Nakata, Koki Abe, Toru Suzuki, Hidemichi Kouzu, Naoya Yama, Nagisa Hanawa, Masato Furuhashi   +14 more
wiley   +1 more source

Critical appraisal of the role of pegloticase in the management of gout

Open Access Rheumatology: Research and Reviews, 2012
Hang-Korng Ea,1,2 Pascal Richette1,21Hôpital Lariboisière, Rheumatology Department, Paris, France; 2University of Paris Diderot, Sorbonne Paris Cité, Paris, FranceAbstract: Gout is a debilitating disease secondary to ...
Ea HK, Richette P
doaj  

HEART FAILURE AND URATE-LOWERING THERAPY: CLINICAL ASPECTS

University therapeutic journal, 2022
Сердечная недостаточность (СН) - широко распространенное заболевание, представляющее глобальную проблему. В этой связи актуальны исследования, направленные на поиск подходов, снижающих риски неблагоприятных событий, ассоциированных с СН. Эксперты солидарны в том, что существует острая потребность в наличии доступных в рутинной клинической практике ...
openaire   +1 more source

Potential Hypoglycemic, Hypolipidemic, and Hypouricemic Bioactive Components From Ampelopsis grossedentata Explored by Affinity Ultrafiltration With Three Enzyme Targets

eFood, Volume 7, Issue 2, April 2026.
By integrating bioaffinity ultrafiltration coupled with HPLC‐MS/MS, this study identified quercetin, myricetrin, dihydromyricetin, and taxifolin from Ampelopsis grossedentata as key inhibitors of α‐glucosidase, pancreatic lipase, and xanthine oxidase, highlighting the promising potential of A.
Siyang Mao, Chu Chu, Yanzhi Xiong, Mengjia Xu, Jian Yang, Mingquan Guo   +5 more
wiley   +1 more source

Long‐Term Opioids in Gout: A Matched Cohort Study From the Veterans Health Administration

Arthritis Care &Research, Volume 78, Issue 3, Page 344-351, March 2026.
Objective Though used frequently to treat flare, risk of long‐term opioid exposure in gout has not been well defined. In this study, we examined the hypothesis that people with gout are more likely than individuals without gout to be prescribed long‐term opioids over time.
Lindsay N. Helget, Bryant R. England, Punyasha Roul, Harlan Sayles, Tuhina Neogi, James R. O'Dell, Joshua F. Baker, Ted R. Mikuls   +7 more
wiley   +1 more source

Adherence and Outcomes with Urate-Lowering Therapy: A Site-Randomized Trial [PDF]

The American Journal of Medicine, 2019
The purpose of this study was to test a pharmacist-led intervention to improve gout treatment adherence and outcomes.We conducted a site-randomized trial (n=1463 patients) comparing a 1-year, pharmacist-led intervention to usual care in patients with gout initiating allopurinol.
Ted R. Mikuls, T. Craig Cheetham, Gerald D. Levy, Nazia Rashid, Artak Kerimian, Kimberly J. Low, Brian W. Coburn, David T. Redden, Kenneth G. Saag, P. Jeffrey Foster, Lang Chen, Jeffrey R. Curtis   +11 more
openaire   +2 more sources

Revisiting the Ethics of Urate‐Lowering Therapy Clinical Trials for Gout Management

Arthritis &Rheumatology, EarlyView.
Lisa K. Stamp, Dien Ho, Nicola Dalbeth
wiley   +1 more source